

ΔΗΜΟΣΙΕΥΣΕΙΣ

ΚΑΛΛΙΡΡΟΗ Ι. ΚΑΛΑΝΤΖΗ

ΚΑΡΔΙΟΛΟΓΟΣ

ΔΙΔΑΚΤΩΡ ΙΑΤΡΙΚΗΣ ΣΧΟΛΗΣ

ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΙΩΑΝΝΙΝΩΝ

Iωάννινα, Σεπτέμβριος 2016

Β. Δημοσιεύσεις σε Ξενόγλωσσα Περιοδικά

1. Milionis HJ, **Kalantzi KJ**, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subject. *J Intern Med* 2005;258:435-41.
2. **Kalantzi KI**, Milionis HJ, Goudevenos IA. Management of the elderly patient with hyperlipidaemia: recent concerns. *Hellenic J Cardiol* 2006;47:93-9. Review.
3. **Kalantzi KJ**, Milionis HJ, Mikhailidis DP, Goudevenos JA. Lipid lowering therapy in the elderly: is there a benefit? *Curr Pharm Des* 2006;12:3945-60.
4. Milionis HJ, **Kalantzi KJ**, Papathanasiou AJ, Kosovitsas AA, Doumas MT, Goudevenos J. Metabolic syndrome and risk of acute coronary syndromes in patients younger than 45 years of age. *Coron Artery Dis* 2007;18:247-52.
5. Papathanasiou A, Milionis H, Toumpoulis I, **Kalantzi K**, Katsouras C, Pappas K, Michalis L, Goudevenos J. Smoking cessation is associated with reduced long-term mortality and the need for repeat interventions after coronary artery bypass grafting. *Eur J Cardiovasc Prev Rehabil* 2007;14:448-50.
6. Milionis HJ, Filippatos TD, Derdemezis CS, **Kalantzi KJ**, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. Excess body weight and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. *Eur J Neurol* 2007;14:762-9.
7. Goudevenos JA, Korantzopoulos P, Papathanasiou A, **Kalantzi K**, Pipilis AG, Katsouras CS, Michalis LK. How many cath labs do we need to perform primary percutaneous coronary interventions in a particular population? *Int J Cardiol* 2008;129:292-3.
8. Tzimas PG, Milionis HJ, Arnaoutoglou HM, **Kalantzi KJ**, Pappas K, Karfis E, Korantzopoulos P, Drossos G, Papadopoulos GS. Cardiac troponin I versus creatine kinase-MB in the detection of postoperative cardiac events after coronary artery bypass grafting surgery. *J Cardiovasc Surg (Torino)* 2008;4:95-101.
9. **Kalantzi K**, Korantzopoulos P, Tzimas P, Katsouras CS, Goudevenos JA, Milionis HJ. The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. *Am Heart J* 2008;155:534-40.
10. Korantzopoulos P, **Kalantzi K**, Siogas K, Goudevenos JA. Long-term prognostic value of baseline C-reactive protein in predicting recurrence of atrial fibrillation after electrical cardioversion. *Pacing Clin Electrophysiol* 2008;31:1272-6.

11. Papathanasiou A, Toumpoulis IK, Milionis HJ, **Kalantzi K**, Katsouras CS, Goudevenos J. Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery. *Coron Artery Dis* 2008;19:619-25.
12. Tzimas P, Milionis HJ, Arnaoutoglou H, **Kalantzi K**, Karfis E, Korantzopoulos P, Pappas K, Drossos G, Papadopoulos G. The value of postoperative troponin levels in predicting long-term mortality after coronary artery bypass surgery. *Ann Card Anaesth* 2009;12:86-8.
13. Pipilis A, Andrikopoulos G, Lekakis J, **Kalantzi K**, Kitsiou A, Toli K, Floros D, Gaita D, Karalis I, Dragomanovits S, Kalogeropoulos P, Synetos A, Koutsogiannis N, Stougiannos P, Antonakoudis C, Goudevenos J; HELIOS group. Outcome of patients with acute myocardial infarction admitted in hospitals with or without catheterization laboratory: results from the HELIOS registry. *Eur J Cardiovasc Prev Rehabil* 2009;16:85-90.
14. Korantzopoulos P, Tzimas P, **Kalantzi K**, Kostapanos M, Vemmos K, Goudevenos J, Elisaf M, Milionis H. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. *Arch Med Res* 2009;40:582-9.
15. Tzimas P, Baikoussis NG, **Kalantzi K**, Papadopoulos G. Is early assessment of cardiac troponin I a valuable predictor of mortality after cardiac surgery? *Interact Cardiovasc Thorac Surg* 2010;10:416-7.
16. Korantzopoulos P, Letsas KP, Christogiannis Z, **Kalantzi K**, Milionis HJ, Massis I, Pappas C, Goudevenos JA. The influence of diabetes on novel electrocardiographic indexes of arrhythmic risk in patients with stable coronary artery disease. *Int J Cardiol* 2011;146:267-8.
17. Korantzopoulos P, Letsas KP, Christogiannis Z, **Kalantzi K**, Massis I, Milionis HJ, Pappas C, Goudevenos JA. Exercise-induced repolarization changes in patients with stable coronary artery disease. *Am J Cardiol* 2011;107:37-40.
18. **Kalantzi KI**, Dimitriou AA, Milionis HJ, Goudevenos IA, Tselepis AD. Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. *J Thromb Haemost* 2011;9:875-8.
19. **Kalantzi KI**, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. *Platelets* 2012;23:121-31.
20. Korantzopoulos P, Letsas KP, Christogiannis Z, **Kalantzi K**, Massis I, Goudevenos JA. Gender effects on novel indexes of heterogeneity of repolarization in patients with stable coronary artery disease. *Hellenic J Cardiol* 2011;52:311-5.
21. Kastorini CM, Milionis HJ, Ioannidi A, **Kalantzi K**, Nikolaou V, Vemmos KN, Goudevenos JA, Panagiotakos DB. Adherence to the Mediterranean diet in relation to acute coronary syndrome

- or stroke nonfatal events: a comparative analysis of a case/case-control study. *Am Heart J* 2011;162:717-24.
22. Tselepis AD, Tsoumani ME, **Kalantzi KI**, Dimitriou AA, Tellis CC, Goudevenos IA. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. *J Thromb Haemost* 2011;9:2371-8.
 23. Tsoumani ME, **Kalantzi KI**, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. *Angiology* 2012;63:547-51.
 24. Tsoumani ME, **Kalantzi KI**, Dimitriou AA, Ntalas IV, Goudevenos IA, Tselepis AD. Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. *Expert Opin Pharmacother* 2012;13:149-58.
 25. Tsoumani ME, **Kalantzi KI**, Goudevenos IA, Tselepis AD. Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions. *Curr Vasc Pharmacol*. 2012 Sep;10(5):539-49. Review.
 26. Korantzopoulos P, Vlachou C, Kotsia A, **Kalantzi K**, Barbouti A, Galaris D, Goudevenos JA. Leukocyte labile iron pool in patients with systolic heart failure. *Hellenic J Cardiol* 2012;53:95-100.
 27. **Kalantzi KI**, Tsoumani ME, Goudevenos IA, Tselepis AD. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. *Expert Rev Clin Pharmacol* 2012;5:319-36. Review.
 28. Kastorini CM, Milionis HJ, **Kalantzi K**, Trichia E, Nikolaou V, Vemmos KN, Goudevenos JA, Panagiotakos DB. The mediating effect of the Mediterranean diet on the role of discretionary and hidden salt intake regarding non-fatal acute coronary syndrome or stroke events: A case/case-control study. *Atherosclerosis* 2012;225:187-93.
 29. **Kalantzi K**, Gouva C, Letsas KP, Vlachopanou A, Foulidis V, Bechlioulis A, Katopodis KP, Goudevenos JA, Korantzopoulos P. The impact of hemodialysis on the dispersion of ventricular repolarization. *Pacing Clin Electrophysiol* 2013;36:322-7.
 30. Goudevenos J, Ntalas I, Xanthopoulou I, **Kalantzi K**, Pipilis A, Alexopoulos D. Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis. *J Thromb Thrombolysis* 2014;37:356-7.
 31. Tsoumani ME, **Kalantzi KI**, Goudevenos IA, Tselepis AD. Clopidogrel Generic Formulations in the Era of New Antiplatelets. A Systematic Review. *Curr Vasc Pharmacol*. *Curr Vasc Pharmacol* 2014;12:766-77.

32. Korantzopoulos P, Letsas KP, Kotsia A, Baltogiannis G, **Kalantzi K**, Kyrlas K, Goudevenos JA. Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients. *World J Cardiol* 2013;5:242-6.
33. Ntalas IV, Milionis HJ, Kei AA, **Kalantzi KI**, Goudevenos JA. Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease: Is There any Place for Novel Agents? *Angiology* 2013;65:473-490.
34. Kastorini CM, Papadakis G, Milionis HJ, **Kalantzi K**, Puddu PE, Nikolaou V, Vemmos KN, Goudevenos JA, Panagiotakos DB. Comparative analysis of a-priori and a-posteriori dietary patterns using state-of-the-art classification algorithms: A case/case-control study. *Artif Intell Med* 2013;59:175-83.
- 35.** Kastorini CM, Milionis HJ, Georgousopoulou E, **Kalantzi K**, Nikolaou V, Vemmos KN, Goudevenos JA, Panagiotakos DB. Defining the Path Between Social and Economic Factors, Clinical and Lifestyle Determinants, and Cardiovascular Disease. *Glob Heart* 2015;10:255-63
- 36.** Ntalas IV, **Kalantzi KI**, Tsoumani ME, Vakalis I, Vasilakopoulos V, Vardakas C, Vemmos K, Voukelatou M, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Dimoulis N, Draganigos A, Efthimiadis I, Thoma M, Kazakos E, Kipouridis N, Konstantinou S, Milionis H, Mpoudakis A, Nikolopoulos D, Peltekis L, Prokopakis N, Sinteles I, Stroumbis C, Terzoudi K, Tsiliias K, Xaraktsis I, Charmpas C, Hatziathanasiou G, Christogiannis Z, Panagiotakos DB, Goudevenos JA, Tselepis AD. Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. *Curr Vasc Pharmacol* 2015;13:809-18
37. Ntalas IV, **Kalantzi KI**, Tsoumani ME, Bourdakis A, Charmpas C, Christogiannis Z, Dimoulis N, Draganigos A, Efthimiadis I, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Hatziathanasiou G, Kazakos E, Kipouridis N, Konstantinou S, Milionis H, Nikolopoulos D, Peltekis L, Prokopakis N, Sinteles I, Stroumbis C, Terzoudi K, Thoma M, Tsiliias K, Vakalis I, Vardakas K, Vasilakopoulos V, Vemmos K, Voukelatou M, Xaraktsis I, Panagiotakos DB, Goudevenos JA, Tselepis AD. J Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. *Cardiovasc Pharmacol Ther* 2016 Apr 14. [Epub ahead of print]

Γ. Δημοσιεύσεις ως ερευνητής σε πολυκεντρικές μελέτες

1. Temporal and spatial distribution of ST-elevation myocardial infarction admissions in a countrywide registry. Pipilis A, Andrikopoulos G, Lekakis J, Zavitsanakis P, Theoharis A, Theodosis A, Liolios C, Papakosmas L, Arvanitis P, Kosmopoulou S, Richter D, Goudevenos J; **Hellenic Infarction Observation Study Group.** Int J Cardiol 2010;142:172-6
2. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; **EUROASPIRE III Study Group.** Eur J Cardiovasc Prev Rehabil. 2009;16:121-37
3. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio GB, Reiner Z, Gaita D, Wood D, Kotseva K, Heidrich J; **EUROASPIRE III Study Group.** J Hypertens. 2011;29:1641-8
4. Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Prugger C, Wellmann J, Heidrich J, De Bacquer D, Perier MC, Empana JP, Reiner Ž, Fras Z, Jennings C, Kotseva K, Wood D, Keil U; **EUROASPIRE III Study Group.** Eur Heart J 2014;35:590-8
5. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology. Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, Tuomilehto J, Wood D, Rydén L; **EUROASPIRE IV Investigators.** Eur Heart J 2015;36:1171-7
6. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, Schnell O, Tuomilehto J, Wood D, Rydén L, Amouyel P, Bruthans J, Conde AC, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milić D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Störk S, Tokgözoğlu L, Vulic D; **EUROASPIRE IV Investigators.** Cardiovasc Diabetol 2015;14:133